Protagonist Therapeutics resolves rusfertide dispute with Zealand Pharma, reduces royalty and milestone payments by 50%

Protagonist Therapeutics, Inc

Royalty rate on rusfertide net sales reduced by 50% under settlement agreement.
All development and sales milestone payments for rusfertide reduced by 50%.
Company to pay $1.0M (Phase 2b milestone) and $1.5M (Phase 3 milestone) within 2 business days.
Additional $1.5M payment due in August 2022.
Future development milestones up to $2.75M; sales milestones up to $50M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.